Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis.
The frequency of extrapyramidal symptoms (EPS) attributed to chlorpromazine among 86 patients who received benztropine for the prevention of EPS (9.3%) was similar to that of the 568 patients who received chlorpromazine alone (10.6%). The data in this small sample indicated that the prophylactic use of benztropine had no effect in reducing the rate of EPS.
D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control*; D001590:Benztropine / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010554:Personality Disorders / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D014326:Tropanes / Q000627:therapeutic use*
D014326:Tropanes; D001590:Benztropine; D002746:Chlorpromazine